Revlimid In Limbo: Market Slams Celgene, Physicians And Payers Take Wait And See Approach
Executive Summary
Absent proof of an overall survival benefit, new data suggesting a link between longer-term use of Celgene Corp.’s blockbuster Revlimid and secondary malignancies in multiple myeloma may encourage a cautious approach to maintenance treatment, threatening a major expansion for the drug.
You may also be interested in...
Celgene Secures Revlimid Frontline Myeloma Approval
Labeling includes new warning for development of second primary malignancies and more language about other kinds of adverse events, but there is already widespread off-label use and analysts don’t expect the warnings to have much impact.
Counting The Cost Of Delay For Revlimid Front-line Myeloma Approval
Fear of second primary cancers foils Celgene’s filing of Revlimid for front-line/maintenance myeloma in Europe. Meanwhile, debate continues about the clinical value and high cost of prolonged treatment, and new options for relapse patients emerge, notably Onyx’s Kyprolis and Celgene’s pomalidomide.
Secondary Cancers Resurface In Updated Revlimid Maintenance Trial Data
Trial investigators proclaim the drug's benefits outweigh its risks and predict maintenance will become the standard of care in multiple myeloma, but investors remain unconvinced.